Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885P - Serum ATG5 protein may determine chemotherapy-related cognitive dysfunction in older patients with cancer
Presenter: Ozgur Tanriverdi
Session: Poster session 12
1886P - Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study
Presenter: Thomas Grellety
Session: Poster session 12
1887P - Effect of logotherapy on chronic sorrow, dignity, and meaning in life of palliative care patients
Presenter: Yasemin Eskigulek
Session: Poster session 12
1888P - PalliScore: Validation of a rapid scoring system for enhancing decision-making in the Emergency Department for cancer patients in palliative care
Presenter: Rafael Carmo
Session: Poster session 12
1889P - Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations
Presenter: Mario di Palma
Session: Poster session 12
1890P - End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic
Presenter: Javaid Iqbal
Session: Poster session 12
1891P - The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity
Presenter: Cho Han Chiang
Session: Poster session 12
1892P - Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies
Presenter: Cho Hung Chiang
Session: Poster session 12
1893P - Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers
Presenter: Anne Dyhl-Polk
Session: Poster session 12
1894P - Pulmonary function test (PFT) and circulating biomarkers in immune-related pneumonitis (irP) in advanced non-small cell lung cancer (aNSCLC): A real-world multidisciplinary experience
Presenter: Loc Carlo Bao
Session: Poster session 12